WO2016136745A1 - キノリン誘導体の苦味抑制方法 - Google Patents
キノリン誘導体の苦味抑制方法 Download PDFInfo
- Publication number
- WO2016136745A1 WO2016136745A1 PCT/JP2016/055268 JP2016055268W WO2016136745A1 WO 2016136745 A1 WO2016136745 A1 WO 2016136745A1 JP 2016055268 W JP2016055268 W JP 2016055268W WO 2016136745 A1 WO2016136745 A1 WO 2016136745A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- basic substance
- cyclopropylaminocarbonyl
- quinolinecarboxamide
- Prior art date
Links
- 235000019658 bitter taste Nutrition 0.000 title claims abstract description 95
- 238000000034 method Methods 0.000 title claims abstract description 51
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 2
- 239000000126 substance Substances 0.000 claims description 64
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims description 61
- 150000003839 salts Chemical class 0.000 claims description 61
- 239000000725 suspension Substances 0.000 claims description 55
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 238000005406 washing Methods 0.000 claims description 32
- 239000003125 aqueous solvent Substances 0.000 claims description 26
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 20
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 12
- 238000004140 cleaning Methods 0.000 claims description 11
- 239000000395 magnesium oxide Substances 0.000 claims description 11
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 11
- -1 carbonate compound Chemical class 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 8
- 239000006188 syrup Substances 0.000 claims description 8
- 235000020357 syrup Nutrition 0.000 claims description 8
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000007910 chewable tablet Substances 0.000 claims description 4
- 239000007919 dispersible tablet Substances 0.000 claims description 4
- 239000007938 effervescent tablet Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 239000000203 mixture Substances 0.000 description 34
- 238000005259 measurement Methods 0.000 description 32
- 230000000052 comparative effect Effects 0.000 description 30
- 229960003784 lenvatinib Drugs 0.000 description 27
- 238000012360 testing method Methods 0.000 description 26
- 229940125904 compound 1 Drugs 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 20
- HWLFIUUAYLEFCT-UHFFFAOYSA-N lenvatinib mesylate Chemical compound CS(O)(=O)=O.C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 HWLFIUUAYLEFCT-UHFFFAOYSA-N 0.000 description 20
- 229960001429 lenvatinib mesylate Drugs 0.000 description 20
- 238000005119 centrifugation Methods 0.000 description 19
- 235000015197 apple juice Nutrition 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 15
- 239000008187 granular material Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 13
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 239000001103 potassium chloride Substances 0.000 description 10
- 235000011164 potassium chloride Nutrition 0.000 description 10
- 239000012488 sample solution Substances 0.000 description 9
- 230000001629 suppression Effects 0.000 description 8
- 238000011084 recovery Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 239000001096 (4-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrochloride Substances 0.000 description 3
- MPQKYZPYCSTMEI-FLZPLBAKSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;dihydrate;hydrochloride Chemical compound O.O.Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 MPQKYZPYCSTMEI-FLZPLBAKSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229960001811 quinine hydrochloride Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 2
- 235000008491 100% juice Nutrition 0.000 description 2
- ZOUIOPVHCKKZRN-UHFFFAOYSA-N 2-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide Chemical compound C=1C=C2C=C(C(N)=O)C(OC)=CC2=NC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 ZOUIOPVHCKKZRN-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000010414 supernatant solution Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 239000004490 capsule suspension Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940041672 oral gel Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a method for suppressing the bitter taste of a medicine.
- composition containing Compound 1 or a salt thereof in order to reduce degradation under humidification / warming conditions or gelation on the surface of the pharmaceutical composition, Compound 1 or a salt thereof, and (i) 5% (w / W)
- Patent Document 2 A pharmaceutical composition containing a compound and / or (ii) silicic acid having a solution or suspension having a pH of 8 or more is known (Patent Document 2).
- Patent Document 4 a composition containing a pharmacologically active ingredient that is an organic sulfonate, a disintegrant, and a water-soluble salt in which the pH of a 2.5% aqueous solution is 3-9 is known (Patent Document 4).
- a pharmaceutical composition such as a capsule dissolved or suspended in water or the like may be administered from the viewpoint of compliance.
- a drug having a bitter taste dissolved or suspended in water or the like when administered to a patient, there is a risk that the patient's dose may be hindered due to the bitter taste, particularly when the patient is a child.
- a dosage form that is easy to swallow such as a suspension, may be selected. There is.
- the recovery rate may not be sufficient, such as the drug substance in the suspension remaining in the container as well as the bitter taste.
- Compound 1 or a pharmaceutically acceptable salt thereof has a bitter taste.
- compound 1 or a pharmaceutically acceptable salt thereof can be mixed with a basic substance such as calcium carbonate to suppress the bitter taste of compound 1 or a pharmaceutically acceptable salt thereof. It was.
- a method for administering a suspension containing Compound 1 or a pharmaceutically acceptable salt thereof and a basic substance each of the following steps: 1) A step of suspending a pharmaceutical composition containing Compound 1 or a pharmaceutically acceptable salt thereof and a basic substance in a container with an aqueous solvent, 2) a step of administering the suspension obtained in step 1) from the container to a patient; 3) a step of washing the container with an aqueous solvent, and 4) a step of administering the cleaning solution obtained in step 3) to the patient,
- the present inventors have found that a suspension of Compound 1 can be administered at a high recovery rate with a liquid volume that can be administered to children without feeling bitterness.
- the present invention provides the following [1] to [33].
- [1] Mixing 4- (3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy) -7-methoxy-6-quinolinecarboxamide or a pharmaceutically acceptable salt thereof with a basic substance 4 A method for inhibiting the bitterness of (3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy) -7-methoxy-6-quinolinecarboxamide.
- Basic substance 0. 1 part by weight of 4- (3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy) -7-methoxy-6-quinolinecarboxamide or a pharmaceutically acceptable salt thereof.
- the basic substance is added in an amount of 0.1% by weight of basic substance per 1 part by weight of 4- (3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy) -7-methoxy-6-quinolinecarboxamide or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition according to any one of [8] to [10], comprising 01 to 50 parts by weight.
- composition according to any one of [8] to [15], wherein the pharmaceutically acceptable salt is mesylate.
- the dosage form is an orally disintegrating tablet, a chewable tablet, an effervescent tablet, a dispersible tablet, a dissolving tablet, a syrup, a syrup agent, a troche, or an oral liquid.
- Pharmaceutical composition [18] The pharmaceutical composition according to any one of [8] to [16], which is a preparation that can be prepared at the time of use, which is prepared by suspending in an aqueous solvent at the time of administration.
- a bitterness inhibitor of 4- (3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy) -7-methoxy-6-quinolinecarboxamide or a pharmaceutically acceptable salt thereof comprising a basic substance .
- Basic added per 1 part by weight of 4- (3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy) -7-methoxy-6-quinolinecarboxamide or a pharmaceutically acceptable salt thereof The bitterness inhibitor according to [19], wherein the substance is 0.01 to 50 parts by weight.
- step 1) includes i) the step of adding the aqueous solvent into the container, ii) the step of leaving the container, and iii) the step of shaking the container.
- step 1) The method according to [26] or [27], wherein in step 1), the aqueous suspension is suspended in 1 to 10 mL.
- step 2) the suspension is suspended with about 3 mL of an aqueous solvent.
- step 3 the organic solvent is washed with 1 to 10 mL of an aqueous solvent.
- a method for treating cancer comprising administering a suspension containing 1) Contains 1 to 24 mg of 4- (3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy) -7-methoxy-6-quinolinecarboxamide or a pharmaceutically acceptable salt thereof and a basic substance Suspending the pharmaceutical composition in a container with an aqueous solvent, 2) a step of administering the suspension obtained in step 1) from the container to a patient; 3) a step of washing the container with an aqueous solvent, and 4) a step of administering the cleaning solution obtained in step 3) to the patient.
- Compound 1 or a pharmaceutically acceptable salt thereof is known as an anticancer agent such as thyroid cancer and treats cancer by the method of the present invention without causing the patient to feel bitterness at the time of administration. Can do.
- the basic substance may be a low molecular compound or a high molecular compound as long as it is a basic substance, and is preferably a basic oxide, a basic carbonate compound, a basic hydroxide, or a carboxyl group. And more preferably, calcium carbonate, magnesium carbonate, potassium carbonate, magnesium oxide, magnesium hydroxide, carboxymethyl starch sodium or croscarmellose sodium, more preferably calcium carbonate or magnesium oxide. Most preferably, it is calcium carbonate.
- the basic substance is preferably mixed in an amount of 0.01 to 50 parts by weight, more preferably 0.03 to 10 parts by weight, and most preferably 0.05 to 5 parts by weight per 1 part by weight of Compound 1.
- the basic substance is a low molecular weight compound
- the basic substance is preferably 0.16 to 80 mol, more preferably 0.3 to 60 mol, most preferably 0.5 to 40 mol per mol of the compound 1. Mix in moles.
- the pharmaceutically acceptable salt means hydrochloride, hydrobromide, tosylate, sulfate, mesylate or esylate, preferably mesylate.
- the “bitter taste” of Compound 1 or a pharmaceutically acceptable salt thereof is measured by the following method.
- Compound 1 or a pharmaceutically acceptable salt thereof is dissolved in 10 mM aqueous potassium chloride solution to prepare a solution having a free form concentration of Compound 1 of 8 mg / mL.
- Additives are added to the solution as necessary, stirred for 30 minutes, and centrifuged to obtain a liquid phase component.
- the bitterness of the liquid phase component is measured using a taste sensor (AC0) for bitterness measurement, and the obtained numerical value is used as an index of bitterness.
- AC0 taste sensor
- “suppressing the bitter taste” of Compound 1 or a pharmaceutically acceptable salt thereof refers to a control comprising Compound 1 or a pharmaceutically acceptable salt thereof in the above-mentioned “bitter taste” measurement method. This means that the relative ratio of the measured value of the sample containing the additive to the control to less than 100%, preferably 70% or less.
- the control containing Compound 1 or a pharmaceutically acceptable salt thereof may be Compound 1 or a pharmaceutically acceptable salt itself, and other components (eg, capsules) as necessary. Etc.).
- the pharmaceutical composition according to the present invention is compound 1 or its pharmacology in a normal administration method or a method in which it is dissolved or suspended in water or the like within a range not impairing a specific function such as entericity.
- the formulation is not particularly limited as long as it is a formulation that may feel a bitter taste of an acceptable salt.
- Agents effervescent tablets, dispersible tablets, dissolving tablets, powders, granules, capsules, syrups, syrups, troches, oral solutions (for example, suspensions) and oral jelly.
- Preferred embodiments include orally disintegrating tablets, chewable tablets, effervescent tablets, dispersible tablets, dissolving tablets, syrups, syrups, which have a relatively long indwelling time in the oral cavity and are likely to feel bitter to patients. Preparation, troche or oral solution.
- dosage forms such as a capsule
- the formulation which can prepare an oral solution at the time of use using solvents, such as water is also contained as a preferable aspect.
- the pharmaceutical composition according to the present invention can be produced by a known method such as the method described in the formulation general rules of the 16th revision Japanese Pharmacopoeia.
- a granule an excipient, a binder, a disintegrant, a solvent, etc. are added to Compound 1 or a pharmaceutically acceptable salt thereof as necessary, and stirring granulation or extrusion granulation is performed.
- Rolling granulation, fluidized bed granulation, spray granulation and the like can be performed.
- a spraying agent containing additives such as water or sucrose, hydroxypropylcellulose, methylcellulose, polyvinylpyrrolidone, etc.
- sucrose spherical granules such as purified sucrose spherical granules, lactose / crystalline cellulose spherical granules, sucrose / starch spherical granules, granular crystalline cellulose, etc. It may be coated. Furthermore, you may sizing and grind
- a pharmaceutical composition according to the present invention which is prepared by suspending in an aqueous solvent such as water when administered, is administered with 1-24 mg of Compound 1 or a pharmaceutically acceptable salt thereof
- a mixture of basic substances is suspended in an aqueous solvent in a container such as a vial, a syringe or a syringe with a nasogastric tube (NG tube).
- NG tube nasogastric tube
- Suspensions can be administered.
- the amount of aqueous solvent used for suspension (may be a sweet drink such as apple juice to suit patient preference) is preferably 1-10 mL, more preferably 2-5 mL, and even more preferably about 3 mL. .
- the container used for suspension is preferably 1-10 mL, more preferably 1 A wash solution washed with ⁇ 5 mL, more preferably about 2 mL of aqueous solvent may be further administered.
- “about” includes a numerical value obtained by rounding off the first decimal place. For example, “about 3” is a range corresponding to 2.5 to 3.4.
- Table 1 shows a list of reagents used for preparation of reference examples, examples and comparative examples, and bitterness measurement.
- Test Example 1 Relative comparison of bitter taste of lenvatinib mesylate and quinine hydrochloride
- Table 2 shows the apparatus and solution used for bitterness measurement
- Table 3 shows the measurement conditions of the sample using the taste recognition apparatus.
- a 10 mM potassium chloride aqueous solution was measured as a blank solution for correction.
- the measurement samples of Reference Example 1 to Reference Example 9 were prepared by dissolving each component described in Table 4 in a 10 mM potassium chloride aqueous solution.
- the measurement by the taste recognition apparatus was performed four times per sample, and only the three measurement results from the 2nd to the 4th were used for the analysis.
- the relative bitterness with respect to Reference Example 7 was calculated according to the following formula, and Table 4 and FIG. The relative bitterness was calculated using only data obtained by a series of continuous measurements.
- Relative bitterness with respect to Reference Example 7 (Measured value of each specimen ⁇ Measured value of 10 mM potassium chloride aqueous solution) ⁇ (Measured value of Reference Example 7 ⁇ Measured value of 10 mM potassium chloride aqueous solution) ⁇ 100%
- Test Example 2 Concentration Dependence of Calcium Carbonate Bitter Taste Inhibition Samples of Examples 1 to 6 and Comparative Example 1 were prepared according to the following procedure, and bitterness was measured according to the same apparatus and method as in Test Example 1. .
- Lenvatinib mesylate was dissolved in a 10 mM aqueous solution of potassium chloride to a concentration of 9.8 mg / mL.
- Components other than lenvatinib mesylate were added to the aqueous solution prepared in (1) so as to have the composition shown in Table 5, and then stirred with a stirrer for 30 minutes.
- the measurement by the taste recognition device was performed 4 times per sample, and only the 3rd measurement result of the 2nd to 4th times was used for the analysis.
- the relative bitterness with respect to Comparative Example 1 was calculated according to the following formula, and Table 5 and FIG. The relative bitterness was calculated using only data obtained by a series of continuous measurements.
- Relative bitterness relative to Comparative Example 1 (Measured value of each specimen ⁇ Measured value of 10 mM potassium chloride aqueous solution) ⁇ (Measured value of Comparative Example 1 ⁇ Measured value of 10 mM potassium chloride aqueous solution) ⁇ 100%
- Lembatinib mesylate 9.8 mg / mL corresponds to lenvatinib free 8 mg / mL.
- Test Example 3 Concentration Dependence of Magnesium Oxide Bitterness Inhibition
- Test Example 2 measurement samples of Examples 7 to 12 and Comparative Example 1 having the compositions shown in Table 6 were prepared, and the bitterness of each sample was measured. did.
- the relative bitterness with respect to Comparative Example 1 decreased as the amount of magnesium oxide added was increased, and the relative bitterness of Examples 7 to 11 was 70% or less.
- Lembatinib mesylate 9.8 mg / mL corresponds to lenvatinib free 8 mg / mL.
- Test Example 4 Bitter taste inhibiting effect of various polymers
- Test Example 2 measurement samples of Examples 13 to 14 and Comparative Examples 1 to 6 having the compositions shown in Table 7 were prepared, and the bitterness of each sample was measured. It was measured.
- the relative bitter taste of Comparative Examples 1 of Examples 13 and 14 containing a sodium salt of a polymer having a carboxyl group was 70% or less.
- Lembatinib mesylate 9.8 mg / mL corresponds to lenvatinib free 8 mg / mL.
- Test Example 5 Bitter taste inhibitory effect of various low molecular weight compounds
- Test Example 2 measurement samples of Examples 15 to 17 and Comparative Examples 1 and 7 to 10 having the compositions shown in Table 8 were prepared. The bitterness of each specimen was measured. As a result, as shown in FIG. 5, the relative bitterness of Comparative Examples 1 of Examples 15 to 17 containing the basic compound was 70% or less.
- Lembatinib mesylate 9.8 mg / mL corresponds to lenvatinib free 8 mg / mL.
- Test Example 6 Litteratinib mesylate-containing composition bitterness-inhibiting effect As in Test Example 2, the bitterness of the measurement samples of Example 18 and Comparative Example 1 having the compositions shown in Table 9 was measured.
- Example 18 The measurement sample of Example 18 was prepared by the following method. Table 10 shows the amount of each raw material used for the preparation of the sized granules. Lembatinib mesylate and calcium carbonate were added to a vertical granulator and mixed. Mannitol, crystalline cellulose (PH101) and low-substituted hydroxypropylcellulose were added to the above mixture and mixed with a vertical granulator. While stirring the above mixture, an aqueous solution of hydroxypropyl cellulose and an appropriate amount of purified water were gradually added in this order. After completion of the addition, the mixture was further stirred with a vertical granulator to obtain granulated granules.
- Table 10 shows the amount of each raw material used for the preparation of the sized granules.
- Lembatinib mesylate and calcium carbonate were added to a vertical granulator and mixed.
- the granulated granules were dried using a fluidized bed with an inflow air temperature set to 70 ° C., and then sized using a comil equipped with a screen having a pore diameter of 1 mm to obtain sized granules.
- the granulated granules, crystalline cellulose (PH102) and talc were mixed in a tumbler mixer to obtain a lenvatinib mesylate-containing composition having the composition shown in Table 9.
- Example 18 After stirring, the centrifugation operation described in (3) of Test Example 2 was performed, and a supernatant portion was collected as a measurement sample. As a result, as shown in FIG. 6, the relative bitterness of Example 18 with respect to Comparative Example 1 was 70% or less.
- Test Example 7 Bitter taste inhibitory effect of each component in the composition containing lenvatinib mesylate Table 11 and FIG. 7 show the compositions and comparative examples of the measurement specimens of Example 19, Comparative Example 1, and Comparative Examples 11 to 15 The measurement result of the relative bitterness with respect to 1 is shown. The relative bitterness was measured using the same procedure as in Test Example 2. In this examination, the bitterness suppression effect of each component of the lenvatinib mesylate-containing composition described in Example 18 was evaluated. As a result, as shown in FIG. 7, the relative bitter taste of Comparative Example 1 of Example 19 containing calcium carbonate was 70% or less.
- Lembatinib mesylate 9.8 mg / mL corresponds to lenvatinib free 8 mg / mL.
- Test Example 8 Dissolution Test of Orally Disintegrating Tablets Using the reagents shown in Table 12, an orally disintegrating tablet was obtained according to the procedure shown in Table 14 based on the formulation shown in Table 13. The dissolution test was performed under the conditions shown in Table 14, and the results shown in FIG. 8 were obtained.
- Table 15 shows a list of reagents not described in Table 1 among the reagents used in the preparation of the following Examples and Comparative Examples and the bitterness measurement.
- Test Example 9 Bitter Taste Inhibitory Effect of Lenvatinib Mesylate-Containing Composition As in Test Example 2, the bitterness of the measurement samples of Example 25 and Comparative Example 1 having the compositions shown in Table 16 was measured.
- Example 25 The measurement sample of Example 25 was prepared by the following method. Capsules containing lenvatinib mesylate having the composition described in Table 16 were prepared by filling 100 mg of lenvatinib mesylate containing composition prepared in Example 18 into No. 4 hypromellose capsules. . A 10 mM potassium chloride aqueous solution was added to the capsule so as to have a concentration shown in Table 16, and then stirred for 30 minutes using a stirrer. After stirring, the centrifugation operation described in (3) of Test Example 2 was performed, and a supernatant portion was collected as a measurement sample. The relative bitterness measurement result of Comparative Example 1 of Example 25 is shown in FIG. As a result, the relative bitterness of Example 25 relative to Comparative Example 1 was 70% or less.
- Test Example 10 Bitter taste inhibitory effect of various low molecular weight compounds
- Test Example 2 measurement samples of Examples 26 to 39 and Comparative Example 1 having the compositions shown in Table 17 and Table 18 were prepared. The bitterness was measured.
- the relative bitterness measurement results of Example 26 to Example 32 with respect to Comparative Example 1 are shown in FIG.
- the relative bitterness measurement results of Example 33 to Example 39 with respect to Comparative Example 1 are shown in FIG.
- the relative bitterness of Example 26 to Example 39 with respect to Comparative Example 1 was 70% or less.
- Lenvatinib mesylate 9.8 mg / mL corresponds to lenvatinib free 8 mg / mL.
- Lenvatinib mesylate 9.8 mg / mL corresponds to lenvatinib free 8 mg / mL. a) Based on the mass composition of the test report issued by the manufacturer, the molar ratio of the sum of metal ions (the sum of aluminum ions and magnesium ions) to lenvatinib mesylate was calculated.
- Test Example 11 Bitter Taste Inhibitory Effect of Various Silicic Acid Compounds
- Test Example 2 measurement samples of Examples 40 to 42 and Comparative Example 1 having the compositions shown in Table 19 were prepared, and the bitterness of each sample was measured. It was measured.
- the relative bitterness measurement results of Example 40 to Example 42 with respect to Comparative Example 1 are shown in FIG. As a result, the relative bitterness of Example 40 to Example 42 relative to Comparative Example 1 was 70% or less.
- Lembatinib mesylate 9.8 mg / mL corresponds to lenvatinib free 8 mg / mL.
- Suspension containing lenvatinib or a salt thereof and administration method a Preparation and administration method of suspension using vials Water or apple juice (100% juice manufactured by Dole), screw cap and 20 mL vial (manufactured by Niezen Kagaku Glass), and syringe (20 mL, manufactured by Baxa) were prepared. Capsules described in Examples 1-3 of US Published Application 2012/0077842 were added to 20 mL vials (1-5 capsules were added to the vials). 3 mL of water or apple juice was injected into the vial using a 20 mL syringe. The vial cap was closed with a screw cap and left for about 10 minutes.
- the vial was shaken for about 3 minutes to dissolve the capsule shell, suspend the granules, open the vial lid, and administer 3 mL of the suspension in the vial to the patient. Washing Step After 3 mL of suspension was administered from the vial, 2 mL of water or apple juice was injected into the vial using another new 20 mL syringe. After closing the lid of the vial with a screw cap, the vial was shaken 10 times, the lid of the vial was opened, and 2 mL of washing solution in the vial was administered to the patient. For 1 to 5 capsules, the total volume of suspension and wash to be administered was 5 mL.
- the syringe was shaken for about 3 minutes to dissolve the capsule shell and suspend the granules.
- the lid was removed from the syringe, the piston was slid, air was evacuated from the syringe, and 3 mL of suspension was administered to the patient from the syringe. Washing Step After 3 mL of suspension was administered from the syringe, the previous lid was attached to the syringe.
- 2 mL of water or apple juice was taken and injected into a syringe with a lid. About 2 cm piston was pushed into the syringe from the end and shaken 10 times. The lid was removed from the syringe, the piston was slid, the air was evacuated, and 2 mL of washing solution was administered to the patient. For 1 to 5 capsules, the total volume of suspension and wash to be administered was 5 mL.
- the syringe was shaken for about 3 minutes to dissolve the capsule shell and suspend the granules.
- the lid was removed from the syringe, and the piston was slid to remove air from the syringe.
- An NG tube was attached to the syringe and 3 mL of suspension was administered to the patient via the NG tube. Washing Step After administering the suspension, the NG tube was removed from the syringe, and the previous lid was attached to the syringe. In another new syringe, 2 mL of water was taken and injected into a syringe with a lid.
- the syringe was shaken 10 times. The lid was removed from the syringe, and the piston was slid to remove air from the syringe.
- An NG tube was attached to the syringe, and 2 mL of the washing solution was administered to the patient via the NG tube. For 1 to 5 capsules, the total volume of suspension and wash to be administered was 5 mL.
- Sample preparation 1-1 Preparation of suspension (vials) Lembatinib 1, 4, 10 mg each 1 capsule or 5 capsules totaling 17 mg (1 mg 3 capsules, 4 mg, 10 mg 1 capsule each) were added to the vial. 3 mL of water or apple juice was added by syringe and the cap was closed. The vial was left for about 10 minutes and then shaken for about 3 minutes to dissolve the capsule shell. The suspension was removed from the vial and a sample solution was prepared by dilution and centrifugation.
- washing solution was taken out from the syringe through the second NG tube, and then 2 mL of water was added by another syringe and the cap was closed. After shaking at least 10 times, the washing solution was taken out from the syringe via the NG tube, and a sample solution was prepared by dilution and centrifugation.
- Step 1 mg, 4 mg, and 10 mg suspensions are each in 50 mL volumetric flasks, and 17 mg (1 mg is 3 capsules, 4 mg, and 10 mg is 1 capsule each) suspension is 200 mL volume.
- NG tube passage test 1-7 1 capsule each of lenvatinib 1, 4, 10 mg or the capsule combination described in Table 30 was suspended in a syringe using 3 mL of water each, and then connected to the NG tube. did.
- Table 31 shows the results of the NG tube permeability test.
- the capsules after moisture-proof packaging the capsules stored at 5 ° C. and those stored for 6 months at 40 ° C./75% RH all passed through the tube, and there was no difference in tube passage.
- the capsules were stored under the above conditions after the moisture-proof packaging.
Abstract
Description
1)化合物1又はその薬剤学的に許容できる塩と塩基性物質とを含む医薬組成物を容器中、水性溶媒で懸濁する工程、
2)工程1)で得られた懸濁液を該容器から患者に投与する工程、
3)水性溶媒で該容器を洗浄する工程及び
4)工程3)で得られた洗浄液を該患者に投与する工程、
を有する投与方法であれば、苦味を感じることなく、小児に投与可能な液量でかつ化合物1の懸濁液を高い回収率で投与することができることを発明者らは見出した。
[1] 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを混合する、4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミドの苦味抑制方法。
[2] 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1重量部当たり、塩基性物質0.01~50重量部を混合する、[1]記載の方法。
[3] 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1モル当たり、塩基性物質0.16~80モルを混合する、[1]記載の方法。
[4] 塩基性物質が、塩基性酸化物、塩基性炭酸化合物又は塩基性水酸化物である、[1]~[3]のいずれか記載の方法。
[5] 塩基性物質が、炭酸カルシウム又は酸化マグネシウムである、[1]~[3]のいずれか記載の方法。
[6] 塩基性物質が、炭酸カルシウムである、[1]~[3]のいずれか記載の方法。
[7] 薬剤学的に許容できる塩が、メシル酸塩である、[1]~[6]のいずれか記載の方法。
[8] 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と苦味を抑制するために有効な量の塩基性物質を含む医薬組成物。
[9] 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩を含む医薬組成物であって、苦味を抑制するために塩基性物質を混合する手段を有する医薬組成物。
[10] 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む、苦味が抑制された、医薬組成物。
[11] 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1重量部当たり、塩基性物質0.01~50重量部を含有する、[8]~[10]のいずれか記載の医薬組成物。
[12] 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1モル当たり、塩基性物質0.16~80モルを混合する、[8]~[10]のいずれか記載の医薬組成物。
[13] 塩基性物質が、塩基性酸化物、塩基性炭酸化合物又は塩基性水酸化物である、[8]~[12]のいずれか記載の医薬組成物。
[14] 塩基性物質が、炭酸カルシウム又は酸化マグネシウムである、[8]~[12]のいずれか記載の医薬組成物。
[15] 塩基性物質が、炭酸カルシウムである、[8]~[12]のいずれか記載の医薬組成物。
[16] 薬剤学的に許容できる塩が、メシル酸塩である、[8]~[15]のいずれか記載の医薬組成物。
[17] 剤形が、口腔内崩壊錠、チュアブル剤、発泡錠、分散錠、溶解錠、シロップ剤、シロップ用剤、トローチ剤又は経口液剤である、[8]~[16]いずれか記載の医薬組成物。
[18] 服用時に水性溶媒で懸濁させて調製される用時調製可能な製剤である、[8]~[16]いずれか記載の医薬組成物。
[19] 塩基性物質からなる、4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩の苦味抑制剤。
[20] 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1重量部当たり、添加される塩基性物質が0.01~50重量部である、[19]記載の苦味抑制剤。
[21] 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1モル当たり、添加される塩基性物質が0.16~80モルである、[19]記載の苦味抑制剤。
[22] 塩基性物質が、塩基性酸化物、塩基性炭酸化合物又は塩基性水酸化物である、[19]~[21]のいずれか記載の苦味抑制剤。
[23] 塩基性物質が、炭酸カルシウム又は酸化マグネシウムである、[19]~[21]のいずれか記載の苦味抑制剤。
[24] 塩基性物質が、炭酸カルシウムである、[19]~[21]のいずれか記載の苦味抑制剤。
[25] 薬剤学的に許容できる塩が、メシル酸塩である、[19]~[24]のいずれか記載の苦味抑制剤。
[26] 下記工程を含む、4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む懸濁液の投与方法:
1)1~24mgの4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む医薬組成物を容器中、水性溶媒で懸濁する工程、
2)工程1)で得られた懸濁液を該容器から患者に投与する工程、
3)水性溶媒で該容器を洗浄する工程及び
4)工程3)で得られた洗浄液を該患者に投与する工程。
[27] 工程1)が、i)前記水性溶媒を容器中に添加する工程、ii)容器を放置する工程及びiii)容器を振とうする工程を含む、[26]記載の方法。
[28] 工程1)において、水性溶媒1~10mLで懸濁する、[26]又は[27]記載の方法。
[29] 工程1)において、約3mLの水性溶媒で懸濁する、[28]記載の方法。
[30] 工程3)において、水性溶媒1~10mLで洗浄する、[26]記載の方法。
[31] 工程3)において、約2mLの水性溶媒で洗浄する、[30]記載の方法。
[32] 1~24mgの4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む懸濁液を投与してなる、癌の治療方法。
[33] 下記工程を含む、4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む懸濁液を投与してなる、癌の治療方法。
1)1~24mgの4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む医薬組成物を容器中、水性溶媒で懸濁する工程、
2)工程1)で得られた懸濁液を該容器から患者に投与する工程、
3)水性溶媒で該容器を洗浄する工程及び
4)工程3)で得られた洗浄液を該患者に投与する工程。
苦味測定に使用する装置及び溶液を表2に、味認識装置を用いた検体の測定条件を表3に示す。補正用のブランク溶液として、10mM塩化カリウム水溶液を測定した。参考例1~参考例9の測定検体は10mM塩化カリウム水溶液に、表4に記載する各成分を溶解することにより調製した。味認識装置による測定は1検体当り4回実施し、2~4回目の3回の測定結果のみを解析に使用した。参考例7に対する相対苦味は下記の式に従い算出し、表4及び図1には3回の測定値の平均値を記載した。なお、相対苦味は連続する一連の測定で得られたデータのみを用いて算出した。
実施例1~実施例6及び比較例1の測定検体を下記の手順に従い調製し、試験例1と同様の装置及び方法に従い苦味を測定した。
(1)10mM塩化カリウム水溶液に9.8mg/mLになるようにレンバチニブメシル酸塩を溶解した。
(2)(1)で調製した水溶液に表5の組成になるようにレンバチニブメシル酸塩以外の成分を添加後、スターラーで30分攪拌した。
(3)遠心分離機を用いて重力加速度20000g以上の条件で20分間遠心分離を実施し、上澄み溶液を測定検体として採取した。なお、目視にて上澄み部分の分離が不十分であると判断した場合は、さらに、重力加速度20000g以上の条件で20分間遠心分離を実施した後、上澄み溶液を測定検体として採取した。ただし、比較例1は(1)で調製した水溶液に固形成分を添加しないため、遠心分離をせずに(1)をそのまま測定検体として使用した。
試験例2と同様に、表6に示す組成を有する実施例7~12及び比較例1の測定検体を調製し、各検体の苦味を測定した。
その結果、図3に示すように、比較例1に対する相対苦味は酸化マグネシウムの添加量を増やすに従い減少し、実施例7~11の相対苦味は70%以下だった。
試験例2と同様に、表7に示す組成を有する実施例13~14及び比較例1~比較例6の測定検体を調製し、各検体の苦味を測定した。
その結果、図4に示すように、カルボキシル基を有するポリマーのナトリウム塩を含有する実施例13及び14の比較例1に対する相対苦味は70%以下だった。
試験例2と同様に、表8に示す組成を有する実施例15~17及び比較例1、比較例7~比較例10の測定検体を調製し、各検体の苦味を測定した。
その結果、図5に示すように、塩基性化合物を含有する実施例15~17の比較例1に対する相対苦味は70%以下だった。
試験例2と同様に、表9に示す組成を有する実施例18及び比較例1の測定検体の苦味を測定した。
その結果、図6に示すように、実施例18の比較例1に対する相対苦味は70%以下だった。
a)73.6mgの整粒顆粒に相当する。
表11及び図7に実施例19及び比較例1、比較例11~比較例15の測定検体の組成と比較例1に対する相対苦味の測定結果を示す。相対苦味の測定は、試験例2と同様の手順を用いて実施した。この検討では、実施例18記載のレンバチニブメシル酸塩含有組成物の各成分の苦味抑制効果を評価した。
その結果、図7に示すように、炭酸カルシウムを含有する実施例19の比較例1に対する相対苦味は70%以下だった。
表12に示した試薬を用い、表13で示された処方に基づき、表14で示された手順に従い、口腔内崩壊錠を得た。表14に示された条件での溶出試験を行い、図8に示す結果が得られた。
試験例2と同様に、表16に示す組成を有する実施例25及び比較例1の測定検体の苦味を測定した。
実施例25の比較例1に対する相対苦味測定結果を図9に示す。その結果、実施例25の比較例1に対する相対苦味は70%以下だった。
a)73.6mgの整粒顆粒に相当する。
試験例2と同様に、表17及び表18に示す組成を有する実施例26~実施例39及び比較例1の測定検体を調製し、各検体の苦味を測定した。
実施例26~実施例32の比較例1に対する相対苦味測定結果を図10に示す。実施例33~実施例39の比較例1に対する相対苦味測定結果を図11に示す。その結果、実施例26~実施例39の比較例1に対する相対苦味は70%以下だった。
a)メーカー発行の試験成績書の質量組成を基に、アンモニウムイオンとレンバチニブメシル酸塩のモル比を算出した。
a)メーカー発行の試験成績書の質量組成を基に、金属イオンの合計(アルミニウムイオンとマグネシウムイオンの合計)とレンバチニブメシル酸塩のモル比を算出した。
試験例2と同様に、表19に示す組成を有する実施例40~実施例42及び比較例1の測定検体を調製し、各検体の苦味を測定した。
実施例40~実施例42の比較例1に対する相対苦味測定結果を図12に示す。その結果、実施例40~実施例42の比較例1に対する相対苦味は70%以下だった。
a.バイアル瓶による懸濁剤の調製及び投与方法
水又はりんごジュース(ドール社製100%ジュース)、スクリューキャップ及び20mLバイアル瓶(日電理科硝子社製)、シリンジ(20mL、Baxa社製)を用意した。
米国公開出願公報第2012/0077842号明細書の実施例1~3に記載されたカプセルを20mLバイアル瓶に加えた(1~5カプセルをバイアルに加えた)。
3mLの水又はりんごジュースを、20mLシリンジを用いてバイアル瓶に注入した。
スクリューキャップでバイアル瓶の蓋を閉め、約10分間放置した。
10分間放置後、約3分間バイアル瓶を振とうして、カプセル殻を溶解させ、顆粒を懸濁させ、バイアル瓶の蓋を開けてバイアル瓶中の懸濁液3mLを患者に投与した。
洗浄工程
3mLの懸濁液をバイアル瓶から投与した後、別の新規な20mLシリンジを用いて、2mLの水又はりんごジュースをバイアル瓶に注入した。
スクリューキャップでバイアル瓶の蓋を閉めた後、バイアル瓶を10回振とうし、バイアル瓶の蓋を開けて、バイアル瓶中の2mLの洗浄液を患者に投与した。
1~5カプセルに対して、投与される懸濁液と洗浄液の全量は5mLであった。
水又はりんごジュース(ドール社製100%ジュース)、蓋及びシリンジ(20mL、Baxa社製)を用意した。
米国公開出願公報第2012/0077842号明細書の実施例1~3に記載されたカプセルを20mLシリンジに加えた(1~5カプセルをシリンジに加えた)。シリンジの先端部を蓋で閉じた。別の新規なシリンジを用いて採取した3mLの水又はりんごジュースを、前記シリンジに注入した。
末端から約2cmピストンをシリンジに押し込んで、シリンジを約10分間放置した。10分間放置後、約3分間シリンジを振とうして、カプセル殻を溶解させ、顆粒を懸濁させた。シリンジから蓋を外し、ピストンをスライドさせて、シリンジから空気を抜き、シリンジから3mLの懸濁液を患者に投与した。
洗浄工程
シリンジから3mLの懸濁液を投与した後、さきほどの蓋をシリンジに付けた。
別の新規なシリンジに、2mLの水又はりんごジュースを取り、蓋付きのシリンジに注入した。
末端から約2cmピストンをシリンジに押し込んで、10回振とうした。
シリンジから蓋を外し、ピストンをスライドさせて、空気を抜いて、2mLの洗浄液を患者に投与した。
1~5カプセルに対して、投与される懸濁液と洗浄液の全量は5mLであった。
水、NGチューブ(40cm、6Fr、Vygon社製)、蓋及びシリンジ(20mL、Baxa社製)を用意した。
米国公開出願公報第2012/0077842号明細書の実施例1~3に記載されたカプセルをシリンジに加えた(1~5カプセルをシリンジに加えた)。シリンジの先端部を蓋で閉じた。別の新規なシリンジを用いて採取した3mLの水を、前記シリンジに注入した。
末端から約2cmピストンをシリンジに押し込んで、シリンジを約10分間放置した。10分間放置後、約3分間シリンジを振とうして、カプセル殻を溶解させ、顆粒を懸濁させた。シリンジから蓋を外し、ピストンをスライドさせて、シリンジから空気を抜いた。NGチューブをシリンジに取り付け、NGチューブを介して3mLの懸濁液を患者に投与した。
洗浄工程
懸濁液を投与した後、NGチューブをシリンジから外し、さきほどの蓋をシリンジに取り付けた。
別の新規なシリンジに、2mLの水を取り、蓋付きのシリンジに注入した。
ピストンを約2cmシリンジの末端から押し込んだ後、10回シリンジを振とうした。シリンジから蓋を外し、ピストンをスライドさせてシリンジから空気を抜いた。シリンジにNGチューブを取り付け、2mLの洗浄液をNGチューブを介して患者に投与した。
1~5カプセルに対して、投与される懸濁液と洗浄液の全量は5mLであった。
材料:
スクリューキャップ及びバイアル瓶(20mL、日電理科硝子製)
蓋及びシリンジ(20mL、BAXA社製)
NGチューブ(40cm、6Fr、Vygon社製)
りんごジュース(100%、ドール社製)
1-1 懸濁液の調製(バイアル瓶)
レンバチニブ1、4、10mgの各1カプセル又は合計17mgとなる5カプセル(1mgを3カプセル、4mg、10mgを各1カプセル)をバイアル瓶に加えた。3mLの水又はりんごジュースをシリンジによって加えてキャップを閉めた。バイアル瓶を約10分間放置した後、約3分間振とうし、カプセル殻を溶解させた。懸濁液をバイアル瓶から取り出し、希釈と遠心分離によりサンプル液を調製した。
洗浄工程の効果を確認するため、3mLの懸濁液を取り出した後、2mLの水又はりんごジュースをシリンジによって加え、バイアル瓶のキャップを閉め、少なくとも10回振とうし、洗浄液をバイアル瓶から取り出し、希釈と遠心分離によりサンプル液を調製した。
バイアルから2mLの洗浄液を取り出した後、2mLの水又はりんごジュースをシリンジによって加えてキャップを閉めた。少なくとも10回振とうし、洗浄液をバイアル瓶から取り出し、希釈と遠心分離によりサンプル液を調製した。
バイアル瓶を用いた調製法と同様に、レンバチニブ1、4、10mgの各1カプセル又は合計17mgとなる5カプセル(1mgを3カプセル、4mg、10mgを各1カプセル)を20mLシリンジに加えた。シリンジに蓋をし、3mLの水又はりんごジュースを別の新規なシリンジで加えた後、末端から約2cmピストンをシリンジに押し込んで、シリンジを約10分間放置した。10分間放置後、約3分間シリンジを振とうして、カプセル殻を溶解させた。ピストンを押し込んで空気をシリンジから抜き、懸濁液をシリンジから取り出し、希釈と遠心分離によりサンプル液を調製した。
洗浄工程の効果を確認するため、3mLの懸濁液を取り出した後、2mLの水又はりんごジュースを別の新規なシリンジによって加え、シリンジの蓋を取り付け、少なくとも10回振とうし、洗浄液をシリンジから取り出し、希釈と遠心分離によりサンプル液を調製した。
シリンジから2mLの洗浄液を取り出した後、2mLの水又はりんごジュースをシリンジによって加えてキャップを閉めた。少なくとも10回振とうし、洗浄液をバイアル瓶から取り出し、希釈と遠心分離によりサンプル液を調製した。
シリンジを用いた調製法と同様に、レンバチニブ1、4、10mgの各1カプセル又は合計17mgとなる5カプセル(1mgを3カプセル、4mg、10mgを各1カプセル)を20mLシリンジに加えた。シリンジに蓋をし、3mLの水を別の新規なシリンジで加えた後、末端から約2cmピストンをシリンジに押し込んで、シリンジを約10分間放置した。10分間放置後、約3分間シリンジを振とうして、カプセル殻を溶解させた。ピストンを押し込んで空気をシリンジから抜き、NGチューブを取り付け、懸濁液はNGチューブを経由させてシリンジから取り出し、希釈と遠心分離によりサンプル液を調製した。
洗浄工程の効果を確認するため、3mLの懸濁液をNGチューブを経由させてシリンジから取り出した後、2mLの水を別の新規なシリンジによって加えた。シリンジに蓋を取り付け、少なくとも10回振とうし、洗浄液をNGチューブ経由でシリンジから取り出し、希釈と遠心分離によりサンプル液を調製した。
NGチューブ経由でシリンジから2mLの洗浄液を取り出した後、2mLの水を別のシリンジによって加えてキャップを閉めた。少なくとも10回振とうし、洗浄液をNGチューブ経由でシリンジから取り出し、希釈と遠心分離によりサンプル液を調製した。
1mg、4mg、10mgの懸濁液は全量をそれぞれ50mLメスフラスコに、17mg(1mgを3カプセル、4mg、10mgを各1カプセル)の懸濁液は全量を200mLメスフラスコに移し、希釈液(メタノール、水、リン酸二水素ナトリウム2水和物=800:200:1(v/v/w))を加えてメスアップした。攪拌と水浴中での超音波処理によって抽出し、遠心分離を行った。
1mg、4mgの最終的なレンバチニブ濃度は、それぞれ0.02mg/mL、0.08mg/mLであった。
10mgについては1mgと4mgと同様に遠心分離後、5mLの上澄み液を10mLフラスコに移し、希釈液で希釈した。10mgの最終的なレンバチニブ濃度は、0.10mg/mLであった。
17mgについては10mgと同様に遠心分離後、5mLの上澄み液を20mLフラスコに移し、希釈液で希釈した。17mgの最終的なレンバチニブ濃度は、0.085mg/mLであった。
レンバチニブの回収率は、表20で示されるHPLC条件で測定した。
バイアル瓶、シリンジ、NGチューブ付きシリンジにおける1,4,10,17mgカプセルの懸濁液の回収率を表21~24に示す。
水とりんごジュースで回収率に違いはなかった。洗浄工程がない場合、回収率は低下した。洗浄回数1回と2回の間では違いなく、少なくとも1回洗浄することでいずれも90%以上の回収率となった。
1-1の記載に従い、1mg、4mg、10mgのカプセルを、各3mLの水又はりんごジュースを用いてバイアル瓶中で懸濁した。初期及び24時間経過後の懸濁液全量をそれぞれ50mLメスフラスコに移し、希釈液(メタノール、水、リン酸二水素ナトリウム2水和物=800:200:1(v/v/w))を加えてメスアップした。攪拌と水浴中での超音波処理によって抽出し、遠心分離を行った。遠心分離後の各上澄み液を表25で示されるHPLC条件で測定し、水又はりんごジュース中でのレンバチニブ懸濁液の初期と24時間経過後の化学的安定性を、不純物Xの検出量により表26~28に示す。
実験結果より不純物Xは初期値から24時間経過しても増加が見られなかったことから、水又はりんごジュース中のレンバチニブ懸濁液は24時間安定であった。
1-4の記載に従い、レンバチニブ1、4、10mgの各1カプセル又は表30に記載したカプセルの組み合わせを、各3mLの水を用いてシリンジ中で懸濁した。表29の条件で測定した各懸濁液の粘度(単位:η/mPas)の結果を表30に示す。防湿包装後のカプセルにおける、5℃保管品と40℃/75%RH(相対湿度)で6箇月間保管したものでは、粘度に違いはなかった。なお,上記条件下でのカプセルの保管は、防湿包装後に実施した。
1-7の記載に従い、レンバチニブ1、4、10mgの各1カプセル又は表30に記載したカプセルの組み合わせを、各3mLの水を用いてシリンジ中で懸濁後、NGチューブを接続した。表31にNGチューブ通過性試験の結果を示す。防湿包装後のカプセルにおける、5℃保管品と40℃/75%RHで6箇月間保管したものでは、全てチューブを通過し、チューブ通過性に違いはなかった。なお,上記条件下でのカプセルの保管は、防湿包装後に実施した。
Claims (33)
- 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを混合する、4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミドの苦味抑制方法。
- 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1重量部当たり、塩基性物質0.01~50重量部を混合する、請求項1記載の方法。
- 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1モル当たり、塩基性物質0.16~80モルを混合する、請求項1記載の方法。
- 塩基性物質が、塩基性酸化物、塩基性炭酸化合物又は塩基性水酸化物である、請求項1~3のいずれか一項記載の方法。
- 塩基性物質が、炭酸カルシウム又は酸化マグネシウムである、請求項1~3のいずれか一項記載の方法。
- 塩基性物質が、炭酸カルシウムである、請求項1~3のいずれか一項記載の方法。
- 薬剤学的に許容できる塩が、メシル酸塩である、請求項1~6のいずれか一項記載の方法。
- 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と苦味を抑制するために有効な量の塩基性物質を含む医薬組成物。
- 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩を含む医薬組成物であって、苦味を抑制するために塩基性物質を混合する手段を有する医薬組成物。
- 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む、苦味が抑制された、医薬組成物。
- 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1重量部当たり、塩基性物質0.01~50重量部を含有する、請求項8~10のいずれか一項記載の医薬組成物。
- 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1モル当たり、塩基性物質0.16~80モルを混合する、請求項8~10のいずれか一項記載の医薬組成物。
- 塩基性物質が、塩基性酸化物、塩基性炭酸化合物又は塩基性水酸化物である、請求項8~12のいずれか一項記載の医薬組成物。
- 塩基性物質が、炭酸カルシウム又は酸化マグネシウムである、請求項8~12のいずれか一項記載の医薬組成物。
- 塩基性物質が、炭酸カルシウムである、請求項8~12のいずれか一項記載の医薬組成物。
- 薬剤学的に許容できる塩が、メシル酸塩である、請求項8~15のいずれか一項記載の医薬組成物。
- 剤形が、口腔内崩壊錠、チュアブル剤、発泡錠、分散錠、溶解錠、シロップ剤、シロップ用剤、トローチ剤又は経口液剤である、請求項8~16いずれか一項記載の医薬組成物。
- 服用時に水性溶媒で懸濁させて調製される用時調製可能な製剤である、請求項8~16いずれか一項記載の医薬組成物。
- 塩基性物質からなる、4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩の苦味抑制剤。
- 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1重量部当たり、添加される塩基性物質が0.01~50重量部である、請求項19記載の苦味抑制剤。
- 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩1モル当たり、添加される塩基性物質が0.16~80モルである、請求項19記載の苦味抑制剤。
- 塩基性物質が、塩基性酸化物、塩基性炭酸化合物又は塩基性水酸化物である、請求項19~21のいずれか一項記載の苦味抑制剤。
- 塩基性物質が、炭酸カルシウム又は酸化マグネシウムである、請求項19~21のいずれか一項記載の苦味抑制剤。
- 塩基性物質が、炭酸カルシウムである、請求項19~21のいずれか一項記載の苦味抑制剤。
- 薬剤学的に許容できる塩が、メシル酸塩である、請求項19~24のいずれか一項記載の苦味抑制剤。
- 下記工程を含む、4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む懸濁液の投与方法:
1)1~24mgの4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む医薬組成物を容器中、水性溶媒で懸濁する工程、
2)工程1)で得られた懸濁液を該容器から患者に投与する工程、
3)水性溶媒で該容器を洗浄する工程及び
4)工程3)で得られた洗浄液を該患者に投与する工程。 - 工程1)が、i)前記水性溶媒を容器中に添加する工程、ii)容器を放置する工程及びiii)容器を振とうする工程を含む、請求項26記載の方法。
- 工程1)において、水性溶媒1~10mLで懸濁する、請求項26又は27記載の方法。
- 工程1)において、約3mLの水性溶媒で懸濁する、請求項28記載の方法。
- 工程3)において、水性溶媒1~10mLで洗浄する、請求項26記載の方法。
- 工程3)において、約2mLの水性溶媒で洗浄する、請求項30記載の方法。
- 1~24mgの4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む懸濁液を投与してなる、癌の治療方法。
- 下記工程を含む、4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む懸濁液を投与してなる、癌の治療方法。
1)1~24mgの4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキシアミド又はその薬剤学的に許容できる塩と塩基性物質とを含む医薬組成物を容器中、水性溶媒で懸濁する工程、
2)工程1)で得られた懸濁液を該容器から患者に投与する工程、
3)水性溶媒で該容器を洗浄する工程及び
4)工程3)で得られた洗浄液を該患者に投与する工程。
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16755489.8A EP3263106B1 (en) | 2015-02-25 | 2016-02-23 | Method for suppressing bitterness of quinoline derivative |
CN201680009824.2A CN107427505A (zh) | 2015-02-25 | 2016-02-23 | 用于抑制喹啉衍生物的苦味的方法 |
DK16755489.8T DK3263106T3 (da) | 2015-02-25 | 2016-02-23 | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
PL16755489.8T PL3263106T3 (pl) | 2015-02-25 | 2016-02-23 | Sposób tłumienia goryczy pochodnej chinoliny |
SG11201706630UA SG11201706630UA (en) | 2015-02-25 | 2016-02-23 | Method for suppressing bitterness of quinoline derivative |
RS20240020A RS65049B1 (sr) | 2015-02-25 | 2016-02-23 | Metoda za suzbijanje gorčine derivata kinolina |
AU2016224583A AU2016224583B2 (en) | 2015-02-25 | 2016-02-23 | Method for suppressing bitterness of quinoline derivative |
JP2017502388A JP6792546B2 (ja) | 2015-02-25 | 2016-02-23 | キノリン誘導体の苦味抑制方法 |
KR1020177022544A KR20170122734A (ko) | 2015-02-25 | 2016-02-23 | 퀴놀린 유도체의 고미 억제 방법 |
RU2017128583A RU2017128583A (ru) | 2015-02-25 | 2016-02-23 | Способ ослабления горечи хинолинового производного |
MX2017010474A MX2017010474A (es) | 2015-02-25 | 2016-02-23 | Metodo para suprimir el amargor de un derivado de quinoleina. |
US15/550,124 US20180028662A1 (en) | 2015-02-25 | 2016-02-23 | Method for Suppressing Bitterness of Quinoline Derivative |
CA2976325A CA2976325C (en) | 2015-02-25 | 2016-02-23 | Method for suppressing bitterness of quinoline derivative |
HRP20231692TT HRP20231692T1 (hr) | 2015-02-25 | 2016-02-23 | Postupak za suzbijanje gorčine derivata kinolina |
BR112017017428-6A BR112017017428A2 (ja) | 2015-02-25 | 2016-02-23 | A bitter taste inhibition method of a quinoline derivative |
LTEPPCT/JP2016/055268T LT3263106T (lt) | 2015-02-25 | 2016-02-23 | Chinolino darinių kartumo sumažinimo būdas |
FIEP16755489.8T FI3263106T3 (fi) | 2015-02-25 | 2016-02-23 | Menetelmä kinoliinijohdannaisen kitkeryyden tukahduttamiseksi |
SI201631787T SI3263106T1 (sl) | 2015-02-25 | 2016-02-23 | Postopek zatiranja grenkobe derivata kinolina |
IL253946A IL253946A0 (en) | 2015-02-25 | 2017-08-10 | A method for suppressing the bitterness of quinoline histories |
US16/038,710 US11090386B2 (en) | 2015-02-25 | 2018-07-18 | Method for suppressing bitterness of quinoline derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562120561P | 2015-02-25 | 2015-02-25 | |
US62/120561 | 2015-02-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/550,124 A-371-Of-International US20180028662A1 (en) | 2015-02-25 | 2016-02-23 | Method for Suppressing Bitterness of Quinoline Derivative |
US16/038,710 Division US11090386B2 (en) | 2015-02-25 | 2018-07-18 | Method for suppressing bitterness of quinoline derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016136745A1 true WO2016136745A1 (ja) | 2016-09-01 |
Family
ID=56789022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/055268 WO2016136745A1 (ja) | 2015-02-25 | 2016-02-23 | キノリン誘導体の苦味抑制方法 |
Country Status (21)
Country | Link |
---|---|
US (2) | US20180028662A1 (ja) |
EP (1) | EP3263106B1 (ja) |
JP (1) | JP6792546B2 (ja) |
KR (1) | KR20170122734A (ja) |
CN (1) | CN107427505A (ja) |
AU (1) | AU2016224583B2 (ja) |
BR (1) | BR112017017428A2 (ja) |
CA (1) | CA2976325C (ja) |
DK (1) | DK3263106T3 (ja) |
FI (1) | FI3263106T3 (ja) |
HR (1) | HRP20231692T1 (ja) |
IL (1) | IL253946A0 (ja) |
LT (1) | LT3263106T (ja) |
MX (1) | MX2017010474A (ja) |
PL (1) | PL3263106T3 (ja) |
PT (1) | PT3263106T (ja) |
RS (1) | RS65049B1 (ja) |
RU (1) | RU2017128583A (ja) |
SG (1) | SG11201706630UA (ja) |
SI (1) | SI3263106T1 (ja) |
WO (1) | WO2016136745A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021511323A (ja) * | 2018-01-19 | 2021-05-06 | アイビバ バイオファーマ インコーポレイテッド | 多標的阻害剤の懸濁組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112190583B (zh) * | 2019-07-08 | 2021-10-29 | 成都苑东生物制药股份有限公司 | 一种乐伐替尼药物组合物及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05194259A (ja) * | 1991-08-30 | 1993-08-03 | Mitsubishi Kasei Corp | 抗消化性潰瘍剤 |
WO2006030826A1 (ja) * | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
WO2008053602A1 (fr) * | 2006-11-02 | 2008-05-08 | Daiichi Sankyo Company, Limited | Dérivé de 5-(1h-1,2,3-triazol-4-yl)-1h-pyrazole |
WO2011021597A1 (ja) * | 2009-08-19 | 2011-02-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体含有医薬組成物 |
Family Cites Families (344)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
GB1458148A (en) | 1974-04-19 | 1976-12-08 | Wyeth John & Brother Ltd | Carbocyclic-fused ring quinoline derivatives |
JPS57123267A (en) | 1981-01-23 | 1982-07-31 | Kansai Paint Co Ltd | Thermosetting paint composition |
US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
ATE85080T1 (de) | 1984-02-17 | 1993-02-15 | Genentech Inc | Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren. |
US4582789A (en) | 1984-03-21 | 1986-04-15 | Cetus Corporation | Process for labeling nucleic acids using psoralen derivatives |
DE8411409U1 (de) | 1984-04-11 | 1984-08-30 | Dr.-Ing. Walter Frohn-Betriebe, 8000 München | Entgasungsventil fuer lager- und/oder transportbehaelter |
US4563417A (en) | 1984-08-31 | 1986-01-07 | Miles Laboratories, Inc. | Nucleic acid hybridization assay employing antibodies to intercalation complexes |
DE3474040D1 (en) | 1984-11-22 | 1988-10-20 | Holsten Brauerei Ag | Beer and process for its preparation |
DE3587500T2 (de) | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
JPS61148115A (ja) | 1984-12-21 | 1986-07-05 | Tooa Eiyoo Kk | 難溶性薬物の徐放性製剤及びその製造法 |
JPS62168137A (ja) | 1985-12-20 | 1987-07-24 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料およびその処理方法 |
CH656535A5 (en) | 1986-01-24 | 1986-07-15 | Spirig Ag | Process for the production of stable pharmaceutical tablets which disintegrate rapidly in water |
JPH07106295B2 (ja) | 1986-07-22 | 1995-11-15 | エーザイ株式会社 | 調湿剤 |
US4743450A (en) | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
CA1339136C (en) | 1987-07-01 | 1997-07-29 | Sailesh Amilal Varia | Amorphous form of aztreonam |
US5009894A (en) | 1988-03-07 | 1991-04-23 | Baker Cummins Pharmaceuticals, Inc. | Arrangement for and method of administering a pharmaceutical preparation |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US4983615A (en) | 1989-06-28 | 1991-01-08 | Hoechst-Roussel Pharmaceuticals Inc. | Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders |
EP0408496A3 (en) | 1989-07-12 | 1992-07-01 | Ciba-Geigy Ag | Solid dosage form for pharmaceutical substances |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
DE69132843T2 (de) | 1990-12-06 | 2002-09-12 | Affymetrix Inc N D Ges D Staat | Identifizierung von Nukleinsäuren in Proben |
GB9105677D0 (en) | 1991-03-19 | 1991-05-01 | Ici Plc | Heterocyclic compounds |
US5367057A (en) | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
JPH04341454A (ja) | 1991-05-16 | 1992-11-27 | Canon Inc | シート収納装置 |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
US5211951A (en) | 1991-07-24 | 1993-05-18 | Merck & Co., Inc. | Process for the manufacture of bioerodible poly (orthoester)s and polyacetals |
US5200194A (en) | 1991-12-18 | 1993-04-06 | Alza Corporation | Oral osmotic device |
EP0648264A4 (en) | 1992-06-03 | 1997-10-01 | Univ Case Western Reserve | BANDAGE ALLOWING THE CONTINUOUS APPLICATION OF ORGANIC PRODUCTS. |
TW271400B (ja) * | 1992-07-30 | 1996-03-01 | Pfizer | |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
JPH06153952A (ja) | 1992-11-26 | 1994-06-03 | Nobuaki Tamamaki | 微量未知二重鎖dna分子の増幅、標識を行うための前処理方法 |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
ATE178794T1 (de) | 1993-01-19 | 1999-04-15 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
US6027880A (en) | 1995-08-02 | 2000-02-22 | Affymetrix, Inc. | Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
JPH07176103A (ja) | 1993-12-20 | 1995-07-14 | Canon Inc | 光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体 |
GB9326136D0 (en) | 1993-12-22 | 1994-02-23 | Erba Carlo Spa | Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
JP3660391B2 (ja) | 1994-05-27 | 2005-06-15 | 株式会社東芝 | 半導体装置の製造方法 |
JPH0848078A (ja) | 1994-08-05 | 1996-02-20 | Nippon Paper Ind Co Ltd | 感熱記録体 |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
US5656454A (en) | 1994-10-04 | 1997-08-12 | President And Fellows Of Harvard College | Endothelial cell-specific enhancer |
JP3207058B2 (ja) | 1994-11-07 | 2001-09-10 | 財団法人国際超電導産業技術研究センター | 超電導体薄膜及びその製造方法 |
IL115256A0 (en) | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
JPH08176138A (ja) | 1994-12-19 | 1996-07-09 | Mercian Corp | イソクマリン誘導体 |
US5948438A (en) | 1995-01-09 | 1999-09-07 | Edward Mendell Co., Inc. | Pharmaceutical formulations having improved disintegration and/or absorptivity |
US5658374A (en) | 1995-02-28 | 1997-08-19 | Buckman Laboratories International, Inc. | Aqueous lecithin-based release aids and methods of using the same |
US5624937A (en) | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
US6579314B1 (en) | 1995-03-10 | 2003-06-17 | C.R. Bard, Inc. | Covered stent with encapsulated ends |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
WO1996040142A1 (en) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
JPH0923885A (ja) | 1995-07-12 | 1997-01-28 | Dai Ichi Seiyaku Co Ltd | 遺伝子発現ライブラリー及びその製造法 |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
WO1997017329A1 (fr) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant |
US5849759A (en) | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
JPH09234074A (ja) | 1996-03-04 | 1997-09-09 | Sumitomo Electric Ind Ltd | アダプター二本鎖dna及びそれを用いたdna増幅方法 |
IL126610A0 (en) | 1996-04-17 | 1999-08-17 | Du Pont Pharm Co | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3- one derivatives as factor xa inhibitors |
US6057100A (en) | 1996-06-07 | 2000-05-02 | Eos Biotechnology, Inc. | Oligonucleotide arrays |
AU721130B2 (en) | 1996-06-28 | 2000-06-22 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
TR199900048T2 (xx) | 1996-07-13 | 1999-04-21 | Glaxo Group Limited | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
JPH10147524A (ja) | 1996-09-20 | 1998-06-02 | Nippon Kayaku Co Ltd | フォルスコリン誘導体含有経口製剤及び医薬製剤の製法 |
NZ334125A (en) | 1996-09-25 | 2000-10-27 | Zeneca Ltd | Quinoline derivatives inhibiting the effect of growth factors such as VEGF |
CA2268129C (en) | 1996-09-30 | 2003-03-11 | Nihon Nohyaku Co., Ltd. | 1,2,3-thiadiazole derivatives or salts thereof and agrohorticultural disease controller and method for using the same |
JPH10114655A (ja) | 1996-10-09 | 1998-05-06 | Kyowa Hakko Kogyo Co Ltd | 固形製剤 |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
BR9713552A (pt) | 1996-11-27 | 2000-01-25 | Pfizer | Derivados de pirimidina bicìclicos condensados |
TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
WO1998032436A1 (en) | 1997-01-29 | 1998-07-30 | Eli Lilly And Company | Treatment for premenstrual dysphoric disorder |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
JP3040486U (ja) | 1997-02-13 | 1997-08-19 | 有限会社ザップ | フィッシングジャケット |
DE69836422T2 (de) | 1997-02-19 | 2007-06-14 | Berlex, Inc., Richmond | N-heterocyclische derivate als nos inhibitoren |
US6090556A (en) | 1997-04-07 | 2000-07-18 | Japan Science & Technology Corporation | Method for quantitatively determining the expression of a gene |
AU7526798A (en) | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
JPH10316576A (ja) | 1997-05-13 | 1998-12-02 | Nissui Pharm Co Ltd | キトサン含有錠剤 |
EP1019040B1 (en) | 1997-05-23 | 2004-09-29 | Bayer Corporation | Aryl ureas for the treatment of inflammatory or immunomodulatory diseases |
WO1998056787A1 (en) | 1997-06-10 | 1998-12-17 | Synthon B.V. | 4-Phenylpiperidine compounds |
US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
AU8283898A (en) | 1997-06-30 | 1999-01-25 | University Of Maryland At Baltimore | Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis |
BE1011251A3 (fr) | 1997-07-03 | 1999-06-01 | Ucb Sa | Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine. |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
JP3765918B2 (ja) | 1997-11-10 | 2006-04-12 | パイオニア株式会社 | 発光ディスプレイ及びその駆動方法 |
JP4194678B2 (ja) | 1997-11-28 | 2008-12-10 | キリンファーマ株式会社 | キノリン誘導体およびそれを含む医薬組成物 |
DE69829412T2 (de) | 1997-12-22 | 2005-07-28 | Bayer Pharmaceuticals Corp., West Haven | Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen |
ES2155817T3 (es) | 1997-12-22 | 2007-06-16 | Bayer Pharmaceuticals Corp. | Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo. |
MXPA00006233A (es) | 1997-12-22 | 2002-09-18 | Bayer Ag | Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas. |
NZ505844A (en) | 1997-12-22 | 2003-10-31 | Bayer Ag | Inhibition of raf kinase using substituted heterocyclic ureas |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
CA2322162A1 (en) | 1998-02-25 | 1999-09-02 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
EP1058538B9 (en) | 1998-03-06 | 2013-01-02 | Aptalis Pharma S.r.l. | Fast disintegrating tablets |
DE19814257A1 (de) | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
JPH11322596A (ja) | 1998-05-12 | 1999-11-24 | Shionogi & Co Ltd | 白金錯体および環状リン酸エステルアミドを含有する抗癌剤 |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
BRPI9911326B8 (pt) | 1998-06-17 | 2021-05-25 | Eisai Co Ltd | análogos macrocíclicos e métodos para seu uso e preparação |
US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
KR100603900B1 (ko) | 1998-10-01 | 2006-07-25 | 노파르티스 아게 | 신규의 서방성 경구 제제 |
ES2188254T3 (es) | 1998-11-19 | 2003-06-16 | Warner Lambert Co | N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas. |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
ATE253051T1 (de) | 1999-01-22 | 2003-11-15 | Kirin Brewery | Chinolinderivate und chinazolinderivate |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
CZ306810B6 (cs) | 1999-02-10 | 2017-07-19 | Astrazeneca Ab | Použití chinazolinového derivátu jako inhibitoru angiogeneze |
GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
JP2000328080A (ja) | 1999-03-12 | 2000-11-28 | Shin Etsu Chem Co Ltd | シートベルト用低摩擦化処理剤 |
YU13200A (sh) | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
WO2000071097A1 (fr) | 1999-05-20 | 2000-11-30 | Takeda Chemical Industries, Ltd. | Composition contenant du sel d'acide ascorbique |
JP4304357B2 (ja) | 1999-05-24 | 2009-07-29 | 独立行政法人理化学研究所 | 完全長cDNAライブラリーの作成法 |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
JP2001047890A (ja) | 1999-08-06 | 2001-02-20 | Toyota Motor Corp | 車両用パワープラントの制御装置 |
AU6762400A (en) | 1999-08-12 | 2001-03-13 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
GT200000158A (es) | 1999-09-28 | 2002-03-16 | Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis. | |
US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
JP2001131071A (ja) | 1999-10-29 | 2001-05-15 | Meiji Seika Kaisha Ltd | 非晶質および非晶質を含有する医薬組成物 |
AU784338B2 (en) | 1999-11-01 | 2006-03-16 | Curagen Corporation | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
US20080241835A1 (en) | 1999-11-01 | 2008-10-02 | Genentech, Inc. | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
MXPA02004879A (es) | 1999-11-16 | 2002-08-30 | Boehringer Ingelheim Pharma | Derivados de urea como agentes antiinflamatorios. |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
CA2395461C (en) | 1999-12-22 | 2010-05-25 | Sugen, Inc. | Methods of modulating c-kit tyrosine kinase function with indolinone compounds |
WO2001047890A1 (fr) | 1999-12-24 | 2001-07-05 | Kirin Beer Kabushiki Kaisha | Quinoline, derives de la quinazoline et medicaments contenant ces substances |
EP1251130B1 (en) | 1999-12-24 | 2005-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Fused purine derivatives |
CA2399358C (en) | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
JP3657203B2 (ja) | 2000-04-21 | 2005-06-08 | エーザイ株式会社 | 銅クロロフィリン塩含有液剤組成物 |
CN1116047C (zh) | 2000-06-05 | 2003-07-30 | 华中科技大学 | 用泥鳅制成的护肝功能食品及其制备方法 |
CA2411278A1 (en) | 2000-06-09 | 2001-12-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
AU2001277621A1 (en) | 2000-08-09 | 2002-03-04 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
ES2318649T3 (es) | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
ATE369894T1 (de) | 2000-11-22 | 2007-09-15 | Novartis Pharma Gmbh | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität |
WO2002044156A2 (en) | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
US6544552B2 (en) | 2001-01-11 | 2003-04-08 | Particle And Coating Technologies, Inc. | Method of producing porous tablets with improved dissolution properties |
JP4808365B2 (ja) | 2001-03-02 | 2011-11-02 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Pcr法 |
US6960580B2 (en) | 2001-03-08 | 2005-11-01 | Millennium Pharmaceuticals, Inc. | Nitrogenous heterocyclic substituted quinoline compounds |
SG152906A1 (en) | 2001-04-06 | 2009-06-29 | Wyeth Corp | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
EP1379545A2 (de) | 2001-04-19 | 2004-01-14 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays |
ES2256466T3 (es) | 2001-04-27 | 2006-07-16 | Kirin Beer Kabushiki Kaisha | Derivado de quinolina que tienen grupo azolilo y derivados de quinazolina. |
JP3602513B2 (ja) | 2001-04-27 | 2004-12-15 | 麒麟麦酒株式会社 | アゾリル基を有するキノリン誘導体およびキナゾリン誘導体 |
JP2003026576A (ja) | 2001-05-09 | 2003-01-29 | Eisai Co Ltd | 味覚改善製剤 |
US6812341B1 (en) | 2001-05-11 | 2004-11-02 | Ambion, Inc. | High efficiency mRNA isolation methods and compositions |
PL392652A1 (pl) | 2001-05-16 | 2010-12-06 | Novartis Ag | Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację |
US6599902B2 (en) | 2001-05-30 | 2003-07-29 | Sugen, Inc. | 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
CN100415720C (zh) | 2001-06-22 | 2008-09-03 | 麒麟医药株式会社 | 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物 |
US20030013208A1 (en) | 2001-07-13 | 2003-01-16 | Milagen, Inc. | Information enhanced antibody arrays |
GB0117144D0 (en) | 2001-07-13 | 2001-09-05 | Glaxo Group Ltd | Process |
JP4827154B2 (ja) | 2001-07-25 | 2011-11-30 | 株式会社オーイズミ | 遊技装置 |
JP3088018U (ja) | 2001-08-02 | 2002-08-30 | ユーエス工業株式会社 | 垂木支持用ブラケットを備えたパイプバンド |
GB0119467D0 (en) | 2001-08-09 | 2001-10-03 | Smithkline Beecham Plc | Novel compound |
US7858321B2 (en) | 2001-09-10 | 2010-12-28 | Meso Scale Technologies, Llc | Methods and apparatus for conducting multiple measurements on a sample |
WO2003024386A2 (en) | 2001-09-20 | 2003-03-27 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
WO2003028711A2 (en) | 2001-09-27 | 2003-04-10 | Novartis Ag | Use of c-kit inhibitors for the treatment of myeloma |
WO2003027102A1 (en) | 2001-09-27 | 2003-04-03 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
AU2002340139A1 (en) | 2001-10-09 | 2003-04-22 | The University Of Cincinnati | Inhibitors of the egf receptor for the treatment of thyroid cancer |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
JP4383870B2 (ja) | 2001-10-17 | 2009-12-16 | 協和発酵キリン株式会社 | 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
PL370137A1 (en) | 2001-11-27 | 2005-05-16 | Wyeth Holdings Corporation | 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
GB0201508D0 (en) | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
JP2003252737A (ja) | 2002-03-04 | 2003-09-10 | Shin Etsu Chem Co Ltd | 口腔用組成物 |
ATE475431T1 (de) | 2002-03-04 | 2010-08-15 | Imclone Llc | Kdr-spezifische humane antikörper und deren anwendung |
WO2003074045A1 (fr) | 2002-03-05 | 2003-09-12 | Eisai Co., Ltd. | Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese |
CA2478411C (en) * | 2002-03-12 | 2010-09-28 | Bristol-Myers Squibb Company | Palatable oral suspension and method |
US20050233991A1 (en) | 2002-03-20 | 2005-10-20 | Ravi Salgia | Methods and compositions for the identification, assessment, and therapy of small cell lung cancer |
US6790852B2 (en) | 2002-04-18 | 2004-09-14 | Hoffmann-La Roche Inc. | 2-(2,6-dichlorophenyl)-diarylimidazoles |
US7598258B2 (en) | 2002-05-01 | 2009-10-06 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
AU2003251968A1 (en) | 2002-07-16 | 2004-02-02 | Children's Medical Center Corporation | A method for the modulation of angiogenesis |
EP3656802A1 (en) | 2002-07-22 | 2020-05-27 | Aspen Aerogels Inc. | Polyimide aerogels, carbon aerogels, and metal carbide aerogels and methods of making same |
US7169936B2 (en) | 2002-07-23 | 2007-01-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments |
US7252976B2 (en) | 2002-08-28 | 2007-08-07 | Board Of Regents The University Of Texas System | Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample |
JP4183193B2 (ja) | 2002-08-30 | 2008-11-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 含窒素芳香環誘導体 |
MXPA05003706A (es) | 2002-10-09 | 2005-07-01 | Kosan Biosciences Inc | Epo d+5-fu/gemcitabina. |
GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
CA2771725C (en) | 2002-10-16 | 2015-08-18 | Takeda Pharmaceutical Company Limited | Solid preparation comprising a non-toxic base and a proton pump inhibitor |
JP4749660B2 (ja) | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
EP1556356B1 (en) | 2002-10-21 | 2006-05-31 | Warner-Lambert Company LLC | Tetrahydroquinoline derivatives as crth2 antagonists |
JPWO2004039782A1 (ja) | 2002-10-29 | 2006-03-02 | 麒麟麦酒株式会社 | Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
DE10250711A1 (de) | 2002-10-31 | 2004-05-19 | Degussa Ag | Pharmazeutische und kosmetische Zubereitungen |
AU2003276453A1 (en) | 2002-11-06 | 2004-06-07 | Cyclacel Limited | Pharmaceutical composition comprising a cdk inhibitor and gemcitabine |
GB0226434D0 (en) | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
ITSV20020056A1 (it) | 2002-11-14 | 2004-05-15 | Alstom Transp Spa | Dispositivo e metodo di verifica di motori software logici di comando di impianti ferroviari, in particolare di impianti di stazione |
AR042042A1 (es) | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
WO2004064730A2 (en) | 2003-01-14 | 2004-08-05 | Cytokinetics, Inc. | Compounds, compositions and methods |
JP3581361B1 (ja) | 2003-02-17 | 2004-10-27 | 株式会社脳機能研究所 | 脳活動測定装置 |
WO2004073632A2 (en) | 2003-02-19 | 2004-09-02 | Biovail Laboratories Inc. | Rapid absorption selective 5-ht agonist formulations |
GEP20084341B (en) | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
CN101053558A (zh) | 2003-03-05 | 2007-10-17 | 细胞基因公司 | 二苯基乙烯化合物及其用途 |
US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
TWI344955B (en) | 2003-03-14 | 2011-07-11 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
RU2312109C2 (ru) | 2003-03-14 | 2007-12-10 | Тайсо Фармасьютикал Ко., Лтд. | Моноклональное антитело и продуцирующая его гибридома |
EA200501552A1 (ru) * | 2003-04-02 | 2006-04-28 | Плива-Истраживанье И Развой Д.О.О. | Фармацевтические композиции с менее выраженным горьким вкусом |
US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
US20070117842A1 (en) | 2003-04-22 | 2007-05-24 | Itaru Arimoto | Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same |
EP1473043A1 (en) | 2003-04-29 | 2004-11-03 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis |
US7107104B2 (en) | 2003-05-30 | 2006-09-12 | Medtronic, Inc. | Implantable cortical neural lead and method |
JP2005008534A (ja) | 2003-06-17 | 2005-01-13 | Soc De Conseils De Recherches & D'applications Scientifiques (Scras) | 抗癌剤及び癌の治療方法 |
KR20120093411A (ko) | 2003-07-10 | 2012-08-22 | 아스트라제네카 아베 | 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 zd6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도 |
EP1653934B1 (en) | 2003-08-15 | 2008-05-14 | AB Science | Use of c-kit inhibitors for treating type ii diabetes |
AU2004268948A1 (en) | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors |
US7485658B2 (en) | 2003-08-21 | 2009-02-03 | Osi Pharmaceuticals, Inc. | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors |
BRPI0413746A (pt) | 2003-08-21 | 2006-10-24 | Osi Pharm Inc | composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo |
US7312243B1 (en) | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
JP2007505938A (ja) | 2003-09-23 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | Vegf受容体阻害剤と化学療法剤の組み合わせ |
EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
KR200340552Y1 (ko) | 2003-10-08 | 2004-02-11 | 주식회사 엘지화학 | 창틀 내부에 블라인드 및 방범창 설치가 용이한 이중창틀 |
JP2005124034A (ja) | 2003-10-20 | 2005-05-12 | Nippon Telegr & Teleph Corp <Ntt> | 発信者の特定及び発信者への呼び返しを可能とする回線設定方法 |
CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
US20080312192A1 (en) | 2003-11-28 | 2008-12-18 | Guido Bold | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases |
US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
KR20060129246A (ko) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
ME02184B (me) | 2003-12-25 | 2016-02-20 | Eisai R&D Man Co Ltd | KRISTALNI OBLIK SOLI 4 -(3-HLORO-4- (CIKLOPROPILAMINOKARBONIL)AMINO-FENOKSI)-7-METOKSI-6-HINOLINKARBOKSAMIDA lLI NJEGOVIH SOLVATA l PROCES ZA NJIHOVU PROIZVODNJU |
EA011402B1 (ru) | 2004-01-23 | 2009-02-27 | Эмджен Инк. | Азотсодержащие гетероциклические производные и их фармацевтические применения |
JP4457108B2 (ja) | 2004-02-27 | 2010-04-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 新規ピリジン誘導体およびピリミジン誘導体(1) |
KR20050091462A (ko) | 2004-03-12 | 2005-09-15 | 한국과학기술연구원 | 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제 |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
RU2385867C2 (ru) | 2004-05-21 | 2010-04-10 | Новартис Аг | Замещенные производные хинолина как ингибиторы митотического кинезина |
CN1960732A (zh) | 2004-06-03 | 2007-05-09 | 霍夫曼-拉罗奇有限公司 | 用吉西他滨和egfr-抑制剂治疗 |
WO2006009765A2 (en) * | 2004-06-18 | 2006-01-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells |
US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
US20050288521A1 (en) | 2004-06-29 | 2005-12-29 | Phytogen Life Sciences Inc. | Semi-synthetic conversion of paclitaxel to docetaxel |
WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
EP2364699A1 (en) | 2004-09-13 | 2011-09-14 | Eisai R&D Management Co., Ltd. | Joint use of sulfonamide based compound with angiogenesis inhibitor |
US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
US7306807B2 (en) | 2004-09-13 | 2007-12-11 | Wyeth | Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease |
EP1794137A4 (en) | 2004-09-27 | 2009-12-02 | Kosan Biosciences Inc | SPECIFIC KINASE INHIBITORS |
AU2005290583A1 (en) | 2004-10-01 | 2006-04-13 | Eisai R & D Management Co., Ltd. | Fine particles-containing composition and manufacturing method therefor |
MX2007004247A (es) | 2004-10-19 | 2007-06-12 | Amgen Inc | Agentes de aglutinacion especifica a angiopoyetina-2. |
JP2008520746A (ja) | 2004-11-22 | 2008-06-19 | キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド | アデノシンa3受容体アンタゴニストを用いる癌及びhif−1が介在する疾患の促進的治療 |
US20090176846A1 (en) | 2004-11-23 | 2009-07-09 | Jei Man Ryu | N-hydroxy-4- {5- [4- (5-isopropyl-2-methyl-1, 3-thiazol-4-yl) phenoxy] pentoxy} benzamidine 2 methanesulfonic acid salt |
EP1827434B1 (en) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
CN100341504C (zh) | 2004-12-01 | 2007-10-10 | 鲁南制药集团股份有限公司 | 佐米曲普坦速释制剂 |
US7612200B2 (en) | 2004-12-07 | 2009-11-03 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
JP2006230816A (ja) | 2005-02-25 | 2006-09-07 | H & A Investment:Kk | サンダル用ホルダー |
EP1859797A4 (en) | 2005-02-28 | 2011-04-13 | Eisai R&D Man Co Ltd | NEW SIMULTANEOUS USE OF A SULPHONAMIDE COMPOUND AND A MEDIUM AGAINST CANCER |
PL1859793T3 (pl) | 2005-02-28 | 2011-09-30 | Eisai R&D Man Co Ltd | Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej |
US20080286282A1 (en) | 2005-02-28 | 2008-11-20 | Eisai R & D Management Co., Ltd. | Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor |
LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
DK1883397T3 (da) | 2005-05-17 | 2010-04-06 | Actelion Pharmaceuticals Ltd | Opløselig bosertan-tablet |
KR20080027775A (ko) | 2005-05-17 | 2008-03-28 | 플렉시콘, 인코퍼레이티드 | 피롤(2,3-b)피리딘 유도체 단백질 키나제 억제제 |
CN102603581B (zh) | 2005-06-22 | 2015-06-24 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
US7550483B2 (en) | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
AU2006260148B9 (en) | 2005-06-23 | 2009-09-17 | Eisai R&D Managment Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)- 7-methoxy-6-quinolinecarboxamide and process for producing the same |
WO2007000347A2 (en) | 2005-06-29 | 2007-01-04 | Roselli, Patrizia | Agonistic and antagonistic peptide mimetics of the vegf alpha-helix binding region for use in therapy |
WO2006105798A2 (en) | 2005-07-11 | 2006-10-12 | Nycomed Danmark Aps | Benzimidazole formulation |
US8648116B2 (en) | 2005-07-21 | 2014-02-11 | Ardea Biosciences, Inc. | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
US20080219977A1 (en) | 2005-07-27 | 2008-09-11 | Isaiah Josh Fidler | Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer |
US20100105031A1 (en) | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
KR100950737B1 (ko) | 2005-08-24 | 2010-03-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신규 피리딘 유도체 및 피리미딘 유도체(3) |
EP1938842A4 (en) | 2005-09-01 | 2013-01-09 | Eisai R&D Man Co Ltd | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS |
CN1308012C (zh) | 2005-11-02 | 2007-04-04 | 广州中医药大学第二附属医院 | 一种治疗脑出血的中药组合物及其制备方法 |
WO2007052849A1 (ja) | 2005-11-07 | 2007-05-10 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質とc-kitキナーゼ阻害物質との併用 |
US20090247576A1 (en) | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
EP1959955B1 (en) | 2005-12-05 | 2010-11-17 | Pfizer Products Inc. | Method of treating abnormal cell growth |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
KR100728926B1 (ko) | 2006-03-20 | 2007-06-15 | 삼성전자주식회사 | 3축 힌지 구조를 갖는 휴대용 전자기기 |
CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
JP5190365B2 (ja) | 2006-08-23 | 2013-04-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | フェノキシピリジン誘導体の塩またはその結晶およびそれらの製造方法 |
KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
CA2662591A1 (en) | 2006-09-07 | 2008-03-13 | Astrazenca Ab | Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase |
CL2007002923A1 (es) | 2006-10-12 | 2008-06-06 | Ptc Therapeutics Inc Soc Organ | Metodo para el tratamiento, prevencion o manejo de una enfermedad asociada con una mutacion sin sentido tal como cancer, diabetes o enfermedad pulmonar, que consiste en administrar a un paciente una cantidad efectiva de acido 3-[5-(2-fluoro-fenil)-[1 |
US20100048503A1 (en) | 2007-01-19 | 2010-02-25 | Eisai R & D Management Co., Ltd. | Composition for treatment of pancreatic cancer |
AU2008206045A1 (en) | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of MEK |
CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
CA2679602A1 (en) | 2007-02-23 | 2008-08-28 | Eisai R&D Management Co., Ltd. | Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of hgfr gene |
WO2008111441A1 (ja) | 2007-03-05 | 2008-09-18 | Kyowa Hakko Kirin Co., Ltd. | 医薬組成物 |
CN101641117B (zh) | 2007-03-05 | 2012-06-13 | 协和发酵麒麟株式会社 | 药物组合物 |
GB2448181B (en) | 2007-04-05 | 2011-11-09 | Ford Global Tech Llc | Vehicle headlight beam controls |
US7807172B2 (en) | 2007-06-13 | 2010-10-05 | University Of Washington | Methods and compositions for detecting thyroglobulin in a biological sample |
PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
WO2009060945A1 (ja) | 2007-11-09 | 2009-05-14 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
AU2009210098B2 (en) | 2008-01-29 | 2013-06-13 | Eisai R & D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
GB2456907A (en) | 2008-01-30 | 2009-08-05 | Astrazeneca Ab | Method for determining subsequent VEGFR2 inhibitor therapy comprising measuring baseline VEGF level. |
JP2011516412A (ja) | 2008-03-05 | 2011-05-26 | ビカス セラピューティクス,エルエルシー | 癌および粘膜炎の治療のための組成物および方法 |
US8044240B2 (en) | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
EP2291350A4 (en) | 2008-04-14 | 2012-09-19 | Ardea Biosciences Inc | COMPOSITIONS AND METHODS FOR THEIR MANUFACTURE AND USE |
US8637554B2 (en) | 2008-05-07 | 2014-01-28 | The Trustees Of The University Of Pennsylvania | Methods for treating thyroid cancer |
JP5699075B2 (ja) | 2008-05-14 | 2015-04-08 | アムジエン・インコーポレーテツド | 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ |
WO2009150256A1 (en) | 2008-06-13 | 2009-12-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Markers for predicting response and survival in anti-egfr treated patients |
MX336723B (es) | 2008-07-11 | 2016-01-28 | Novartis Ag | Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek. |
WO2010048304A2 (en) | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
WO2010086964A1 (ja) | 2009-01-28 | 2010-08-05 | 株式会社 静岡カフェイン工業所 | がん治療のための併用療法 |
US20120164148A1 (en) | 2009-08-07 | 2012-06-28 | The Wistar Institute | Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer |
JP2013502421A (ja) | 2009-08-21 | 2013-01-24 | マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー | 癌治療のためのcd44融合タンパク質の使用方法 |
EP2293071A1 (en) | 2009-09-07 | 2011-03-09 | Universität Zu Köln | Biomarker for colorectal cancer |
EP2586443B1 (en) | 2010-06-25 | 2016-03-16 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
WO2012008563A1 (ja) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
EP2596364B1 (en) | 2010-07-19 | 2015-12-16 | F.Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
JP2013538338A (ja) | 2010-07-19 | 2013-10-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗癌治療への応答可能性の増大した患者を同定する方法 |
SG187018A1 (en) | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
KR20130091750A (ko) | 2010-07-19 | 2013-08-19 | 에프. 호프만-라 로슈 아게 | 유방암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커 |
WO2012019300A1 (en) | 2010-08-10 | 2012-02-16 | Siu K W Michael | Endometrial cancer biomarkers and methods of identifying and using same |
US20120077837A1 (en) | 2010-09-24 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Anti-tumor agent |
RU2568258C2 (ru) | 2011-02-28 | 2015-11-20 | Саншайн Лейк Фарма Ко., Лтд | Замещенные соединения хинолина и способы их использования |
EP2741784B1 (en) | 2011-03-02 | 2017-05-17 | Board Of Regents, The University Of Texas System | Tusc2 therapies |
CN103476943A (zh) | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | 用于增强治疗癌症的局部和全身性免疫调节疗法的组合 |
CA2828946C (en) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
WO2012154935A1 (en) | 2011-05-12 | 2012-11-15 | Eisai R&D Management Co., Ltd. | Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof |
ES2622401T3 (es) | 2011-05-17 | 2017-07-06 | Eisai R&D Management Co., Ltd. | Método de predicción de la eficacia de un inhibidor de la angiogénesis |
ES2705950T3 (es) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
TW201840336A (zh) | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
EP2849784A1 (en) | 2012-05-16 | 2015-03-25 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
EA038920B1 (ru) | 2012-10-02 | 2021-11-10 | Бристол-Майерс Сквибб Компани | Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли |
AU2013353745A1 (en) | 2012-12-04 | 2015-06-11 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of breast cancer |
CA3150658A1 (en) | 2013-01-18 | 2014-07-24 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
AU2014221775B2 (en) | 2013-02-28 | 2017-08-24 | Eisai R&D Management Co., Ltd. | TETRAHYDROIMIDAZO[1,5-d][1,4]OXAZEPINE DERIVATIVE |
MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
ES2705698T3 (es) | 2013-06-26 | 2019-03-26 | Eisai R&D Man Co Ltd | Terapia de combinación para el tratamiento del cáncer que comprende eribulina y lenvatinib |
US9174998B2 (en) | 2013-12-25 | 2015-11-03 | Eisai R&D Management Co., Ltd. | (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
KR20220153677A (ko) | 2014-02-04 | 2022-11-18 | 인사이트 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합 |
JO3783B1 (ar) | 2014-08-28 | 2021-01-31 | Eisai R&D Man Co Ltd | مشتق كوينولين عالي النقاء وطريقة لإنتاجه |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
CN107801379B (zh) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | 抗癌剂 |
AU2016284383B2 (en) | 2015-06-23 | 2020-08-20 | Eisai R&D Management Co., Ltd. | Crystal of (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1- yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4- hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2Hpyrazino[ 2,1-c][1,2,4]triazine-1-(6H)-carboxamide |
US20200375975A1 (en) | 2016-04-15 | 2020-12-03 | Eisai R&D Management Co., Ltd. | Treatment of Renal Cell Carcinoma with Lenvatinib and Everolimus |
-
2016
- 2016-02-23 DK DK16755489.8T patent/DK3263106T3/da active
- 2016-02-23 LT LTEPPCT/JP2016/055268T patent/LT3263106T/lt unknown
- 2016-02-23 SI SI201631787T patent/SI3263106T1/sl unknown
- 2016-02-23 JP JP2017502388A patent/JP6792546B2/ja active Active
- 2016-02-23 BR BR112017017428-6A patent/BR112017017428A2/ja not_active Application Discontinuation
- 2016-02-23 KR KR1020177022544A patent/KR20170122734A/ko not_active Application Discontinuation
- 2016-02-23 SG SG11201706630UA patent/SG11201706630UA/en unknown
- 2016-02-23 CN CN201680009824.2A patent/CN107427505A/zh active Pending
- 2016-02-23 RU RU2017128583A patent/RU2017128583A/ru not_active Application Discontinuation
- 2016-02-23 MX MX2017010474A patent/MX2017010474A/es unknown
- 2016-02-23 RS RS20240020A patent/RS65049B1/sr unknown
- 2016-02-23 PT PT167554898T patent/PT3263106T/pt unknown
- 2016-02-23 PL PL16755489.8T patent/PL3263106T3/pl unknown
- 2016-02-23 WO PCT/JP2016/055268 patent/WO2016136745A1/ja active Application Filing
- 2016-02-23 HR HRP20231692TT patent/HRP20231692T1/hr unknown
- 2016-02-23 CA CA2976325A patent/CA2976325C/en active Active
- 2016-02-23 EP EP16755489.8A patent/EP3263106B1/en active Active
- 2016-02-23 US US15/550,124 patent/US20180028662A1/en not_active Abandoned
- 2016-02-23 AU AU2016224583A patent/AU2016224583B2/en active Active
- 2016-02-23 FI FIEP16755489.8T patent/FI3263106T3/fi active
-
2017
- 2017-08-10 IL IL253946A patent/IL253946A0/en unknown
-
2018
- 2018-07-18 US US16/038,710 patent/US11090386B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05194259A (ja) * | 1991-08-30 | 1993-08-03 | Mitsubishi Kasei Corp | 抗消化性潰瘍剤 |
WO2006030826A1 (ja) * | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
US20080214604A1 (en) | 2004-09-17 | 2008-09-04 | Hisao Furitsu | Medicinal Composition |
WO2008053602A1 (fr) * | 2006-11-02 | 2008-05-08 | Daiichi Sankyo Company, Limited | Dérivé de 5-(1h-1,2,3-triazol-4-yl)-1h-pyrazole |
WO2011021597A1 (ja) * | 2009-08-19 | 2011-02-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体含有医薬組成物 |
US20120077842A1 (en) | 2009-08-19 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Quinoline derivative-containing pharmaceutical composition |
Non-Patent Citations (4)
Title |
---|
EISAI CO., LTD.: "Report on the Deliberation Results Lenvima Capsules 4 mg", EVALUATION AND LICENSING DIVISION, PHARMACEUTICAL AND FOOD SAFETY BUREAU MINISTRY OF HEALTH, LABOUR AND WELFARE, 26 January 2015 (2015-01-26), pages 1 - 100, XP055863234, Retrieved from the Internet <URL:https://www.pmda.go.jp/files/000210264.pdf> [retrieved on 20211118] |
MASHA S H LAM: "Extemporaneous Compounding of Oral Liquid Dosage Formulations and Alternative Drug Delivery Methods for Anticancer Drugs", PHARMACOTHERAPY, vol. 31, no. 2, 1 February 2011 (2011-02-01), pages 164 - 192, XP055863221 |
TAKANORI TANAKA ET AL.: "Tandospirone Citrate Jo 10mg 'Amel' no Seibutsugakuteki Dotosei Shiken", SHIN'YAKU TO RINSHO, vol. 57, no. 6, June 2008 (2008-06-01), pages 936 - 951, XP009505465 * |
WALSH JENNIFER; CRAM ANNE; WOERTZ KATHARINA; BREITKREUTZ JOERG; WINZENBURG GESINE; TURNER ROY; TULEU CATHERINE: "Playing hide and seek with poorly tasting paediatric medicines: Do not forget the excipients", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 73, 12 March 2014 (2014-03-12), Amsterdam , NL , pages 14 - 33, XP028855087, ISSN: 0169-409X, DOI: 10.1016/j.addr.2014.02.012 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021511323A (ja) * | 2018-01-19 | 2021-05-06 | アイビバ バイオファーマ インコーポレイテッド | 多標的阻害剤の懸濁組成物 |
Also Published As
Publication number | Publication date |
---|---|
PT3263106T (pt) | 2024-01-12 |
RS65049B1 (sr) | 2024-02-29 |
DK3263106T3 (da) | 2024-01-08 |
US20180028662A1 (en) | 2018-02-01 |
IL253946A0 (en) | 2017-10-31 |
SI3263106T1 (sl) | 2024-02-29 |
PL3263106T3 (pl) | 2024-04-02 |
HRP20231692T1 (hr) | 2024-03-15 |
RU2017128583A (ru) | 2019-03-25 |
CA2976325A1 (en) | 2016-09-01 |
RU2017128583A3 (ja) | 2019-03-25 |
LT3263106T (lt) | 2024-01-10 |
EP3263106A1 (en) | 2018-01-03 |
EP3263106B1 (en) | 2023-10-25 |
SG11201706630UA (en) | 2017-09-28 |
FI3263106T3 (fi) | 2024-01-03 |
MX2017010474A (es) | 2017-11-28 |
US11090386B2 (en) | 2021-08-17 |
JP6792546B2 (ja) | 2020-11-25 |
AU2016224583A1 (en) | 2017-08-31 |
EP3263106A4 (en) | 2018-08-29 |
AU2016224583B2 (en) | 2021-06-03 |
CN107427505A (zh) | 2017-12-01 |
CA2976325C (en) | 2023-07-04 |
KR20170122734A (ko) | 2017-11-06 |
JPWO2016136745A1 (ja) | 2017-11-30 |
BR112017017428A2 (ja) | 2018-04-03 |
US20180318422A1 (en) | 2018-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3725778B1 (en) | Formulations of enzalutamide | |
US20230381194A1 (en) | Suspension for oral administration comprising amorphous tolvaptan | |
RU2527766C2 (ru) | Таблетки и гранулированные порошки, содержащие 6-фтор-3-гидрокси-2-пиразинкарбоксамид | |
JP2003508386A (ja) | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 | |
PT1858490E (pt) | Formas farmacêuticas com propriedades farmacocinéticas melhoradas | |
JP5103173B2 (ja) | ジヒドロピリジン系化合物の分解を防止する方法 | |
WO2008077591A2 (en) | Pharmaceutical formulation comprising neurokinin antagonist | |
BRPI0710914A2 (pt) | forma de dosagem e método para o tratamento de dependência, adição e supressão de nicotina, em particular para uso na terapia para parar de fumar | |
EP2514422B1 (en) | Elution stabilized teneligliptin preparation | |
KR20150015500A (ko) | 엔테카비어의 약제학적 조성물 및 제조 방법 | |
WO2016136745A1 (ja) | キノリン誘導体の苦味抑制方法 | |
EP2432459A2 (en) | Oral compositions of celecoxib | |
US8133513B2 (en) | Solid preparation having improved solubility | |
JP7359764B2 (ja) | ジアミン誘導体を含む顆粒剤 | |
JP6181044B2 (ja) | カプセル剤 | |
JP2005060310A (ja) | 不快な味をマスキングする経口投与用製剤 | |
Charan et al. | Immediate drug release dosage form: A review | |
WO2013117793A1 (es) | Composición farmacéutica sólida de cilostazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16755489 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017502388 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 253946 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2976325 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20177022544 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2016755489 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201706630U Country of ref document: SG Ref document number: MX/A/2017/010474 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017017428 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016224583 Country of ref document: AU Date of ref document: 20160223 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017128583 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112017017428 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170814 |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2024/0020 Country of ref document: RS |